Autophagy Maintains Vascular Function Through a Novel Glycolysis-linked Pathway Regulating eNOS

Sponsor
University of Utah (Other)
Overall Status
Completed
CT.gov ID
NCT04200560
Collaborator
(none)
16
1
2
46.9
0.3

Study Details

Study Description

Brief Summary

Aging is inevitable and is the primary risk factor for developing cardiovascular disease. The molecular mechanisms that drive vascular dysfunction in the context of aging are incompletely understood. The overall hypothesis is that the age-related decline in endothelial cell (EC) autophagy leads to arterial dysfunction. This study will determine whether physiological shear-stress affects autophagosome formation and nitrous oxide (NO) generation in ECs.

Condition or Disease Intervention/Treatment Phase
  • Other: Rhythmic Handgrip Exercise
  • Other: Chronic Exercise Training
N/A

Detailed Description

It is hypothesized that genetic autophagy suppression prevents shear-stress induced purinergic signaling to endothelial nitrous oxide synthase (eNOS) and this pathway will be evaluated in primary arterial ECs obtained from older adult (> 60 years) and adult (18-30 years) subjects before and following rhythmic handgrip exercise that elevates brachial artery shear-rate similarly in both groups. ECs will be used to quantify markers of EC autophagy, eNOS activation, and NO generation. The study will also determine whether exercise-training attenuates the aging-associated decline in EC autophagy, and whether intact autophagy is required for training-induced vascular improvements. To evaluate this potential, it will be determined whether one-limb rhythmic handgrip exercise training by older adult (> 60 y) human subjects is sufficient to elevate basal and shear-induced EC autophagy initiation, eNOS activation, and NO generation vs. the contralateral sedentary limb. Results from this work have tremendous potential to reveal a new therapeutic target and approach for restoring / maintaining vascular function in the aging population.

Study Design

Study Type:
Interventional
Actual Enrollment :
16 participants
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Autophagy Maintains Vascular Function Through a Novel Glycolysis-linked Pathway Regulating eNOS
Actual Study Start Date :
Jul 1, 2018
Actual Primary Completion Date :
May 30, 2022
Actual Study Completion Date :
May 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Healthy Adult Subjects

Healthy adult subjects (18 - 30 years) will be assessed for markers of EC autophagy, eNOS activation, and NO generation before and after Rhythmic Handgrip Exercise

Other: Rhythmic Handgrip Exercise
60 minute rhythmic handgrip exercise

Experimental: Healthy Older Adult Subjects

Healthy older adult subjects (> 60 years) will be assessed for markers of EC autophagy, eNOS activation, and NO generation before and after Rhythmic Handgrip Exercise and after Chronic Exercise Training.

Other: Rhythmic Handgrip Exercise
60 minute rhythmic handgrip exercise

Other: Chronic Exercise Training
Handgrip exercise training consisting of three 60-minute training sessions per week for eight weeks.

Outcome Measures

Primary Outcome Measures

  1. Change in biomarker beclin-1 after Rhythmic Handgrip Exercise [60 min]

  2. Change in biomarker Atg3 after Rhythmic Handgrip Exercise [60 min]

  3. Change in biomarker Atg5 after Rhythmic Handgrip Exercise [60 min]

  4. Change in biomarker Atg7 after Rhythmic Handgrip Exercise [60 min]

  5. Change in biomarker Lamp1 after Rhythmic Handgrip Exercise [60 min]

  6. Change in biomarker Lamp2 after Rhythmic Handgrip Exercise [60 min]

  7. Change in biomarker p62 after Rhythmic Handgrip Exercise [60 min]

  8. Change in biomarker beclin-1 after chronic exercise training [8 weeks]

  9. Change in biomarker Atg3 after chronic exercise training [8 weeks]

  10. Change in biomarker Atg5 after chronic exercise training [8 weeks]

  11. Change in biomarker Atg7 after chronic exercise training [8 weeks]

  12. Change in biomarker Lamp1 after chronic exercise training [8 weeks]

  13. Change in biomarker Lamp2 after chronic exercise training [8 weeks]

  14. Change in biomarker p62 after chronic exercise training [8 weeks]

Secondary Outcome Measures

  1. Change in radial arterial diameter after Rhythmic Handgrip Exercise [60 min]

  2. Change in radial arterial flow rate after Rhythmic Handgrip Exercise [60 min]

  3. Change in biomarker p-eNOSS1177 after Rhythmic Handgrip Exercise [60 min]

  4. Change in radial arterial diameter after chronic exercise training [8 weeks]

  5. Change in radial arterial flow rate after chronic exercise training [8 weeks]

  6. Change in biomarker p-eNOSS1177 after chronic exercise training [8 weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion criteria:
  • Candidates must be between 18 and 90 y of age

  • Candidates must be free of overt disease as assessed by a) medical history; b) standard blood chemistries (chem. 7 panel), c) ECG at rest; d) limb vascular examination (ankle-brachial BP index > 0.9); e) resting BP < 140/90 mmHg; and f) skinfold % body fat assessment.

  • Subjects will have a body mass index (BMI) between 19 and 30 and have plasma glucose concentrations < 7.0 mmol/L under fasting conditions and < 11.1 mmol/L at 120 minutes of an oral glucose tolerance test (OGTT)

Exclusion criteria

  • Candidates <18 or >90 y of age

  • Candidates demonstrating abnormal ECG, ankle-brachial BP index <0.9, resting BP > 140/90

  • Candidates demonstrating a BMI <19 or > 30

  • Candidates demonstrating plasma glucose concentrations > 7.0 mmol/L under fasting conditions and > 11.1 mmol/L at 120 minutes of an oral glucose tolerance test (OGTT)

  • Candidates demonstrating dyslipidemia (plasma total cholesterol > 240 mg/dl with LDL-cholesterol > 160 mg/dl)

  • Candidates reporting a history of myocardial infarction, unstable cardiac ischemia, recent cardiac catheterization, carotid artery disease, transient ischemic attack

  • Women taking hormone replacement therapy (HRT) currently or in the preceding year will be excluded from the proposed studies due to the direct vascular effects of HRT.

Contacts and Locations

Locations

Site City State Country Postal Code
1 VA Medical Center Salt Lake City Utah United States 84148

Sponsors and Collaborators

  • University of Utah

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
John David Symons, Professor, University of Utah
ClinicalTrials.gov Identifier:
NCT04200560
Other Study ID Numbers:
  • 00077971
First Posted:
Dec 16, 2019
Last Update Posted:
Aug 22, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by John David Symons, Professor, University of Utah
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 22, 2022